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Abstract
Hepatitis C virus (HCV) treatment has the potential to cure the leading cause of cirrhosis
and hepatocellular carcinoma. However, only those deemed eligible for treatment have
the possibility of this cure. Therefore, understanding the determinants of HCV treatment
eligibility is critical. Given that effective communication with and trust in healthcare provid-
ers significantly influences treatment eligibility decisions in other diseases, we aimed to
understand patient-provider interactions in the HCV treatment eligibility process. This pro-
spective cohort study was conducted in the VA Pittsburgh Healthcare System. Patients
were recruited after referral for gastroenterology consultation for HCV treatment with inter-
feron and ribavirin. Consented patients completed semi-structured interviews and vali-
dated measures of depression, substance and alcohol use, and HCV knowledge. Two
coders analyzed the semi-structured interviews. Factors associated with patient eligibility
for interferon-based therapy were assessed using multivariate logistic regression. Of 339
subjects included in this analysis, only 56 (16.5%) were deemed eligible for HCV therapy
by gastroenterology (GI) providers. In the multivariate logistic regression, patients who
were older (OR = 0.96, 95%CI = 0.92–0.99, p = .049), reported concerns about the GI pro-
vider (OR = 0.40, 95%CI = 0.10–0.87, p = 0.02) and had depression symptoms (OR =
0.32, 95%CI = 0.17–0.63, p = 0.001) were less likely to be eligible. Patients described bar-
riers that included feeling stigmatized and poor provider interpersonal or communication
skills. In conclusion, we found that patients’ perceptions of the relationship with their GI
providers were associated with treatment eligibility. Establishing trust and effective
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communication channels between patients and providers may lower barriers to potential
HCV cure.
Introduction
Hepatitis C virus (HCV) affects 4 million people and is the leading cause of cirrhosis in the
United States [1]. Despite increasingly efficacious treatments for HCV, less than 20% of
infected patients have received HCV treatment [2,3]. Financial, logistical, and medical prob-
lems as well as patient-specific concerns all contribute to these low treatment rates. While the
shift to interferon-free therapies has simplified the assessment of treatment eligibility, this
assessment requires HCV diagnosis and referral for specialty care. Despite systematic efforts to
increase rates of disease recognition and subsequent referrals to specialty clinics [4], up to 66%
of referred patients do not attend the scheduled consultation for HCV therapy [5]. For those
who do attend their appointments with specialized providers, potentially important barriers
must be overcome before a patient is deemed eligible for treatment. The determination of treat-
ment eligibility involves medical testing to define liver disease stage and relevant comorbid
conditions, and the need for this workup has been associated with decreases in the number of
patients enrolling into treatment programs [5].
Beyond tangible medical criteria, guidelines established by the American Association for the
Study of Liver Diseases also address less well defined criteria for treatment eligibility, including
adherence [6]. This requirement for eligibility is based on the need for consistent drug expo-
sure in order to achieve a sustained viral response (SVR), which may become increasingly
important with the high costs of the more recently introduced antiviral agents at a time of lim-
ited resources. The true impact of adherence and other non-medical eligibility criteria on treat-
ment rates have not been fully explored, but may contribute to the significant variability in
treatment eligibility, which ranges from 4 to 50%[7–9].
Providers continue to determine whether patients are eligible for HCV treatment, even in
the era of interferon-free treatments. Given that the medical contraindications to interferon-
free HCV treatment are far less, the non-medical criteria for eligibility, such as perceived
adherence, are likely to become increasingly important. The aim of this study was to evaluate
the determinants of provider-determined eligibility for HCV treatment with a focus on the
patient perspective.
Patients and Methods
Subjects
The VA Pittsburgh IRB approved this study with a waiver of HIPAA and a waiver of written
informed consent. Interested patients were orally consented by research staff who then docu-
mented this oral consent in the research records. Subjects were considered eligible if they were
referred to gastroenterology/hepatology (GI) providers to consider HCV treatment. We mailed
invitations to each potential subject and followed up with a second invitation if there was no
response within 1 week. Patients who still had not responded were invited to participate by
clinic staff when they were called with routine appointment reminders. A study coordinator
contacted all potential participants who expressed interest to obtain informed consent and
complete an interview before and after their gastroenterology appointments. After the initial
appointment with GI, all participants were asked to provide feedback about their experience,
the information they learned, and their current attitudes toward treatment (S1 File). These
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interviews were approximately one hour and conducted over the telephone. Interviews were
conducted prior to patients knowing their eligibility status, which was determined after follow-
up. The flow of patients through the clinical and research procedures is outlined in Fig 1. Sub-
sequent to the interview, patient records were abstracted to determine treatment eligibility.
This protocol was approved by the VA Pittsburgh Institutional Ethics Review Board.
Determination of Treatment Eligibility
Charts of the participants were systematically reviewed by members of the research team from
the initial visit to 18 months or until patients began therapy, whichever came first. The notes
by the GI providers were evaluated to determine treatment eligibility as a dichotomous out-
come. Participants were deemed eligible if the provider explicitly confirmed that the partici-
pant was an appropriate candidate for therapy and/or should move toward treatment. In the
absence of this documentation by the pre-determined study end-point of 18 months, partici-
pants were operationally deemed ineligible for the purposes of this study.
Semi-structured Interview
We conducted semi-structured interviews after the consultation appointment (please see S1
File for the interview script). We digitally recorded each interview and used a “quasi-statistical”
qualitative methodology developed by Crabtree and Miller to identify qualitative codes and to
determine their frequency [10]. Through an iterative process, we constructed a qualitative
codebook designed to capture patient-expressed barriers and facilitators to HCV treatment.
The senior author and the master coder (SLZ and NKB) led teams of two trained coders as
they analyzed audio files and abstracted qualitative data. Coders met to reconcile differences
until 100% agreement was reached. The adjudicated codes were then added into a final data-
bank that was then used for all subsequent analyses.
Qualitative domains
We coded each potential barrier or facilitator to treatment initiation that participants dis-
cussed. The iterative review for the codebook construction was used to generate a list of themes
and functioned as the framework for the coding of all the interviews. Based on this framework,
we coded five main barrier and facilitator domains: physical symptoms and quality of life,
access and coordination of care, provider-patient communication, personal barriers/facilita-
tors, and social barriers/facilitators. All qualitative themes were coded as dichotomous (not
mentioned = 0, yes mentioned = 1)
Questionnaires
Patients provided demographic information and completed a telephone interview that
included 5 validated quantitative measures. The Patient Education about Hepatitis C (PEAHC)
collects baseline knowledge about HCV, its complications, risk factors, behaviors that exacer-
bate liver damage, current treatment options, treatment side effects, and treatment effective-
ness rates [11–13]. It is scored by counting the number of items answered correctly. The
Center for Epidemiologic Studies-Depression (CES-D), a widely used screening measure for
assessing the presence and severity of depression, was used because it has been validated in
HCV [14]. It uses 4-point Likert scales with item scores ranging from 0 = "rarely" to 3 = "most
of days," with a score of 16 representing potentially relevant depression. In a screening of HCV
patients CES-D had a Cronbach’s alpha between 0.88–0.90 when used on pre- and post-treat-
ment patients [14]. The Alcohol Use Disorders Identification Test (AUDIT) was employed to
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identify hazardous drinkers [15]. It uses a 5-point scale from 0 = “never” to 5 = “daily use” with
a score< 8 indicates non-hazardous alcohol use, 8–14 indicating hazardous, and>14 as
dependent drinking. A review of research on the AUDIT found that the scale generally has a
Cronbach's alpha reported to be in the 0.80's [16]. The Drug Abuse Screening Test 10 (DAST
10), a 10-item questionnaire, assesses drug use during the preceding 12 months [17]. It has a
Cronbach’s alpha of 0.87 and uses 5-point Likert scales ranging from never to daily use [18].
Statistical Methods
Descriptive statistics (means and standard deviations for continuous variables and frequencies
for categorical variables) were computed to describe the sample. For the demographic and sur-
vey variables, we compared those who were eligible for treatment to those who were not using
Student’s t tests (or Mann-Whitney) for continuous data and Chi-Square tests (or Fisher’s
exact) for categorical data, to identify potentially important statistical covariates of treatment
eligibility. For the qualitative variables, sets of the qualitative variables were aggregated into
domains and coded as mentioned vs. not mentioned. We used logistic regression to identify
the important qualitative predictors of treatment eligibility first with specific variables within a
domain and then with domains themselves. To handle non-identifiability and multicollinearity
that arose when specific qualitative variables within domains were sparse (<5 responses per
item), we dropped the sparse specific qualitative variables and only included the larger
domains.
Potentially relevant variables were identified based on p<0.15 in the univariate analyses and
were included in multivariable logistic regression models that combined qualitative and quanti-
tative data. Backwards elimination was then used to find a parsimonious final model.
Fig 1. Clinical and Study Flow.
doi:10.1371/journal.pone.0148596.g001
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Multicollinearity was assessed by computing variance inflation factors (VIFs) for the full multi-
variate model prior to the final backwards elimination. VIF statistics>10 indicate the presence
of collinearity. Stata (release 12; 2011, College Station, TX, StataCorp, LP) was used in all
analyses.
Results
Participants
Six hundred and six patients were referred to GI to discuss the initiation of HCV antiviral ther-
apy between 2006 and 2010 and were eligible for the PATHS study. Of the 477 subjects con-
sented to be in the study, 39 could not be reached and an additional 76 people were excluded as
their interviews were incomplete due to technical problems with the audio recorders. Of the
362 original PATHS study participants, an additional 23 people were excluded as they did not
complete the semi-structured interview given after the initial GI consult, resulting in 339
(50.1%) study subjects in this analysis. The inter-coder reliability kappa statistic was 0.66–1.00,
based on double coding 25% of the interviews. As shown in Table 1, participants were 98%
male, which is in keeping with the demographics of the VA, 54%White and had a mean age of
54. The majority of the group had low annual incomes and low levels of education. Only 25%
of the subjects were working, and over 36% lived with a spouse/partner. Based on the survey
data, 34% of the cohort met criteria for hazardous or dependent alcohol use, 55% occasionally
or consistently took illicit drugs, and 47% met the definition of depression based on the CES-D
score of16.
Univariate Analysis
Fifty-four (16%) of the 339 participants were deemed eligible for treatment within 18 months
of their index appointment. The factors associated with treatment eligibility in the univariate
analysis are shown in Table 2. Those who were deemed eligible were significantly more likely
to live with a partner. Other factors that had a borderline association with eligibility were lower
levels of depressive symptoms, knowledge of HCV, and employment. For the qualitative data,
several identified themes were associated with higher or lower likelihood of treatment eligibil-
ity. Participants were more likely to be deemed eligible for therapy if they described treatment
in terms of improving their quality of life. Conversely, subjects who reported barriers related to
the relationship with the GI provider were significantly less likely to become eligible for treat-
ment. Additionally, the qualitative domain “patient barriers”—defined by expressed lack of
interest in treatment, trouble with decision making, and/or financial or travel concerns—was
significantly associated with decreased treatment eligibility (p = 0.045) in univariate analysis.
Multivariate analysis
The results of the multivariable model (Table 3) indicate that older participants (p = 0.049)
and persons with depressive symptoms (p = 0.001) were significantly less likely to be eligible
for treatment. In addition, barriers related to the relationship with the GI provider (p = 0.020)
were associated with lower treatment eligibility. Multi-collinearity was not found for this
model (all VIFs were<10).
Relationship with GI Provider: Detailed Thematic Analysis
Within the category coded as barriers related to the relationship with the GI provider, we
examined specific themes that helped to clarify patients’ views. Themes were then extracted
from the narrative data of the participants who were not deemed eligible to provide further
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insights into the barriers they experienced. First, participants discussed problems related to
general interpersonal communication with the GI provider, focusing primarily on a feeling of
personal connection. For example, when asked about whether the Veteran felt comfortable
sharing needed information with the GI provider, one participant stated: “No. They weren't
interested in anything I had to say.” Another described the provider as robotic or going
through the clinical routine without emphasizing an interpersonal connection: “I don't know. I
guess it just seems that [the provider] seemed to go through it by rote. I didn't feel much
Table 1. Demographic and Clinical Characteristics.
Characteristic Study Sample (n = 339)
Age (mean±sd) 54.2±6.9
Comorbidity Index (mean±sd) 1.1±1.7
Gender N(%)
Male 332 (97.9)
Female 7 (2.1)
Race N(%)
White 184 (54.3)
Black 153 (45.1)
Other 2 (0.6)
Education N(%)
High School or Less 174 (51.3)
Some Education after High School 123 (36.3)
At Least 4 Year College Degree 40 (11.8)
Income N(%)
<10K 123 (36.3)
10–19K 123 (36.3)
20K+ 85 (25.1)
Living Arrangement N(%)
Alone 125 (36.9)
With Spouse/Partner 125 (36.9)
With Relatives 46 (13.5)
With Non-Relatives 43 (12.7)
Current Work Status N(%)
Currently Working 86 (25.4)
Disabled or Retired 168 (49.5)
Not Working 78 (23.0)
AUDIT–C N(%)
Non-Hazardous Alcohol Use 223 (65.8)
Hazardous Alcohol Use 47 (13.9)
Dependent Alcohol Use 68 (20.0)
DAST N(%)
Non-Use 150 (44.3)
Occasional Use 76 (22.4)
Consistent Use 112 (33.0)
CES-D (Total) (mean ±sd) 16.9±12.7
CES-D N(%)
<16 180 (53.1)
16+ 159 (46.9)
PEAHC (mean±sd) Post appointment % correct 83.2 ±7.0
doi:10.1371/journal.pone.0148596.t001
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interest on [the provider’s] part as far as me as a person. It was more like [the provider] was
going through a series of motions that [the provider has] done for so many times that. . .[it
was] very mechanical.” Such experiences were also expressed in statements about a lack of
interpersonal warmth. For example, when asked what negative experiences a patient had with
their GI provider, one man stated: “I didn't really get the sense that they really cared about you
as a patient, you know what I mean?” Consistent with the perceived problems in patient-pro-
vider communication, participants identified communication as an important area for
improvement, such as shown in the following statement:
It's all about communication skills. You know, you can't just sit there and tell somebody:
"Hey, gee, you've got hepatitis C and it kills you and all this," because [the providers] don't
have it. So they have no feeling. . .they send you out of the office with a potential life-threat-
ening disease. They don't care.
Table 2. Variables Meeting Selection Criteria from the Univariate Analyses of Treatment Eligibility.
Eligible (n = 54) Not Eligible (n = 285) p-valuea.
Living Arrangement N (%) 0.022
Alone 12 (22.2) 113 (39.6)
With Spouse/Partner 23 (42.6) 102 (35.8)
With Relatives 13 (24.1) 33 (11.6)
With Non-Relatives 6 (11.1) 37 (13.0)
Work Status 0.071
Working or Retired 38 (70.4) 163 (57.2)
Disabled 16 (29.6) 122 (42.8)
CES-D Total Score 13.6±10.3 17.5±13.0 0.054
CES-D 0.006
<16 38 (70.4) 142 (49.8)
16+ 16 (19.6) 143 (50.2)
PEAHC (% Correct) 85.0±5.8 82.9±7.2 0.067
QUALITATIVE DATAb.
Facilitator: Quality of Life 46 (85.2) 192 (67.4) 0.017
Facilitator: Patient: Decision Making 4 (7.4) 8 (2.8) 0.097
Barrier: Past Treatment Stopped by Providerc 2 (3.7) 1 (0.4) 0.050
Barrier: Provider-Patient Relationship 9 (16.7) 92 (32.3) 0.025
Barrier: Patient 4 (7.4) 51 (17.9) 0.045
Barrier: Social Work 6 (11.1) 15 (5.3) 0.098
a For continuous variables, p-value is based on Student’s t-tests (or Mann Whitney), for categorical variables, p-value based on chi-square tests (or
Fisher’s Exact)
b Shown is the number of times the facilitator or barrier was mentioned
c Not included in the multivariable modeling model due to small numbers
doi:10.1371/journal.pone.0148596.t002
Table 3. Multivariable Logistic Regression Model for Treatment Eligibility.
Age 0.96 0.92–0.99 0.049
Barrier-Provider Patient Relationship 0.40 0.10–0.87 0.020
Depressive symptoms 0.32 0.17–0.63 0.001
doi:10.1371/journal.pone.0148596.t003
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Secondly, participants noted that they had not received sufficient information from the pro-
vider in order to understand their disease or the treatment options. One patient, when asked
whether there was additional information he would have liked to learn from his provider,
added: “Well one thing I'd have liked to find out was: what was the treatment for hepatitis C?
Find out if I was going to go through it? They wouldn't even give me that information.” Partici-
pants felt compelled to obtain information independently: “The only thing is that I don't have
enough information on really what's going on. I've been going to the library to do my own
research, and I don't know a whole lot of information on it.”
One additional important point emerged that related to communication skills, as participants
preferred an open discussion with their providers rather than receiving hand-outs or pamphlets.
Beyond the need for discussions that focus on individually relevant facts, participants also con-
sidered the available information as too complex or too confusing to guide their decisions:
No. I'm just at a loss right now. I can't quite help you much, except I got to say: try to edu-
cate people on what the hell's going on with them. You know, don't send them literature.
Ask the people. My eyes are so shot to the level that I can't see no more. You know what I'm
saying? And they give me a big pamphlet with all these wee little lines and I'm going to sit
there with a magnifying glass and make my way through it? And then how much of it did I
retain? How much of it did I gather? You need to have an explanatory class on this mess.
Finally, some participants felt stigmatized by healthcare providers. One man felt judged
when he told his provider that he used Vicodin for pain, adding “but the way they try to
pigeon-hole me and I'm a damn junkie or something, you know? That's what bothers me.”
Another patient, who described himself as a moderate drinker, expressed his frustration with
his GI provider:
[The provider] said, "Well, we have a program and if you are in the program you can't
drink." I said, "Well, that's fine." And then says, "Well, I tell you, I'll give you the informa-
tion, but we can't do anything for you until for 6 months until you stop drinking." You
know, like "what?" And [the provider] says to me that [they] believe I drank more than that.
It's really pissing me off at the time. “Well, wait a minute, you know. Yeah, I do drink on
occasion and I know how much I consume because . . . I don't drink at home.” I said, "And
if I do drink at home it's because I went out to dinner with my wife and I'm the designated
driver and so I don't drink and drive." "Yeah right," you know, was [the provider’s] com-
ment. So, I'm already into this really pissed off place, you know?
Such responses were also expressed by patients who described themselves as former or
active drug users: “If you are a drug addict or used to be a drug addict, they look down upon
you. . .I don't think it's right, you know, because I had tracks on my arm. They look at you like
you are eewh! You know?” Nonverbal signals similarly conveyed a sense of stigmatization.
Such perceptions primarily focused on the standard precautions that are routinely imple-
mented when handling potentially infectious biological materials, as shown in the following
statement: “They—you're in the hospital and they act like you have leprosy, you know. They
put signs up, you know, about communicable disease or something like on that order, you
know. That gets pretty frustrating.”
Discussion
Patients describing more positive relationships with their hepatology providers were more
likely to be deemed eligible for HCV treatment. While other studies have demonstrated the
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importance of other factors in HCV treatment eligibility, this large, prospective, mixed-methods
study adds to the literature by providing a rich contextual understanding of how the quality of
patient-provider interactions may influence measurable health outcomes. The themes emerging
from the qualitative analysis include the importance of communication and connection between
patients and providers. Patients spoke of desiring more warmth from providers and wanting
information in the form of conversation rather than pamphlets. Stigma also emerged as a major
theme for patients, particularly among those with a history of prior drug use.
This large, mixed-methods cohort adds to a growing body of literature regarding HCV
treatment eligibility. In this cohort, specialists found only 16% of participants to be eligible for
interferon-based treatment; this is consistent with previously-published interferon-based treat-
ment eligibility rates [19,20]. Prior studies assessing treatment eligibility have focused on tradi-
tional quantitative factors and not on qualitative factors. For example, a study of 4,084
Veterans found that 32% were eligible for treatment based on standard criteria and that non-
eligibility was associated with ongoing substance use and medical and psychiatric comorbidi-
ties [21]. Among those deemed eligible, an additional 24% declined to be treated. Another
study with a treatment eligibility rate of 16–26% using standard guidelines and that age was sig-
nificantly associated with treatment eligibility as determined by a clinician [20], consistent
with our findings. Similarly, another study found that non-treatment was associated with active
substance abuse, appointment non-attendance, early-stage disease, and medical and psychiat-
ric comorbidities [7]. Medical comorbidities, cytopenias, hepatocellular carcinoma, older age,
and advanced liver disease were also associated with non-eligibility in yet another study [9].
While several studies have assessed medical factors associated with treatment ineligibility,
there have not been large studies of qualitative factors associated with HCV treatment eligibil-
ity. This is notable because medical factors may be less relevant in the interferon-free treatment
era. While these treatments dramatically decrease side effects and medical contraindications to
therapy, the providers continue to determine patient eligibility for these costly treatment regi-
mens. The qualitative factors associated with this determination are critical to understand in
order to maximize treatment eligibility in a new era.
Existing literature supports the importance of the patient-provider relationship to health
outcomes. Communication is a critical part of the patient-provider relationship. We have pre-
viously described that 40% of patients with HCV perceived communication problems with
their treating clinician [22]. This poor communication on the part of the provider can lead to
the patient perception of stigma [23–27]. Additionally, the overall quality of the patient-pro-
vider relationship has been associated with medication adherence [28]. The importance of
patient-provider rapport has been demonstrated to be associated with improved HIV medica-
tion adherence [23,29] and with improved outcomes [30]. It is unclear from this study whether
the patient-perceived relationship issues could be improved with changes in the provider’s
communication skills. Given that communication skills are teachable [31], this should be
assessed in future studies. Additionally patient-directed interventions may aid in rapport and
relationship building. For example, patients may be empowered with more knowledge about
the treatment process if the educational materials were derived with patient input.
In addition to the patient-provider relationship, age and depression were also independently
associated with decreased eligibility for HCV therapies. Advanced age and severe depression
were contraindications to HCV therapy at the time of this study, per national guidelines[32].
These contraindications were somewhat justified by studies of interferon-based regimens.
Advanced age has been associated with lower sustained viral clearance rates in some [33,34] but
not all [20] studies, and with increased overall comorbidity and typically a longer duration of
HCV infection. These factors may translate to more advanced disease, making treatment more
difficult. Similar to advanced age, depression was a relative contraindication to interferon-based
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treatment [35] and thus significantly correlated with a lower likelihood to move toward treat-
ment eligibility [36,37] in other studies. Consistent with our findings, a prior study demon-
strated that 40% of HCV infected patients with coexisting psychiatric diseases were not eligible
because of the severity of mental health disorder and/or did not complete their evaluations [38].
Correspondingly, mental health treatment has been shown to improve HCV treatment eligibil-
ity [39,40]. Though depression is not a contraindication to interferon-free HCV treatment regi-
mens, patients with psychiatric comorbidities have had higher rates of incomplete evaluations
in the past [41], which may still affect decisions about using the newer, very expensive treat-
ments in this population. Thus, the finding that depression and age were significantly associated
with treatment ineligibility in this study is consistent with prior literature.
While the prospective design, large cohort, and rich data set provide important insight, this
study has several limitations. Our results are, in part, derived from qualitative methods which
limit generalizability of findings, but which impart an important richness in detail. From a
methodological perspective, qualitative research relies on the open-ended response from each
participant, which provides important in-depth information, but also requires rigorous coding.
Our study used a semi-structured interview guide that asked questions in a specific and pre-
determined order that helped to reduce inconsistent responses. The advantage of the open-
ended approach is that, by incorporating the patients’ words, we can discover barriers and facil-
itators that were not previously considered and would not have been included in an a priori
survey design. Additionally, we applied a rigorous approach with multiple raters and achieved
high inter-coder reliability. In addition, the generalizability of findings may be limited by our
focus on US Veterans’ treatment within a single VA Healthcare System. A VA sample is unique
in that Veterans are provided complete healthcare and medications are at a near 100% subsi-
dized rate. In private systems, insurance coverage may be a more relevant consideration in
determining treatment eligibility, particularly in the context of more expensive interferon-free
treatments. As such we were able to include the voice of low income patients who would likely
be excluded in other healthcare systems due to limitations of insurance coverage. Also, this
cohort included predominantly White and Black men but few members of other gender or
racial/ethnic groups. Additional research will be needed to determine the extent to which the
problems identified in this healthcare system are prevalent elsewhere. A final limitation of this
study was the lack of data regarding disease characteristics or severity. These data were not col-
lected at the time of the study as the IRB deemed such clinical data unnecessary to capturing
patients’ perceived barriers to treatment given the qualitative goals of the study. The disease-
level variables associated with treatment eligibility have been previously well-characterized
[7,9,20,21,38,41]; this study adds to the existing data by providing a qualitative perspective.
Despite these limitations, our qualitative and survey data provide a rich contextual understand-
ing of the patient perspective regarding their relationship with providers, an understanding
which will be critically important in the era of interferon-free treatment.
In conclusion, we found that patients’ perceptions of the relationship with their GI provid-
ers were associated with treatment eligibility. Establishing trust and effective communication
channels between patients and providers may lower barriers to potential HCV cure. Future
studies should assess how to optimize patient-provider rapport in order to improve treatment
rates in the context of newer HCV treatments.
Supporting Information
S1 File. Patient Attitude Toward Hepatitis Study (PATHS) Interview Script Semi-Struc-
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